Financial Statements — RNA
Balance Sheet
(in millions USD)| Metric | Q2
2026 | Q1
2026 |
|---|
| Cash & Equivalents | 72.33 | 267.85 |
| Short-term Investments | 191.57 | -- |
| Total Current Assets | 275.05 | 285.57 |
| Property, Plant & Equipment | 4.07 | 4.34 |
| Total Non-current Assets* | 5.46 | 6.80 |
| Total Assets | 280.51 | 292.36 |
| Accounts Payable | 3.51 | 0.81 |
| Total Current Liabilities | 31.51 | 21.91 |
| Total Non-current Liabilities* | 34.43 | 36.35 |
| Total Liabilities | 65.94 | 58.26 |
| Retained Earnings | (8.06) | 12.13 |
| Total Stockholder Equity | 214.58 | 234.10 |
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2
2026 | Q1
2026 |
|---|
| Total Revenue | 3.00 | 19.64 |
| Research & Development | 15.34 | 16.66 |
| Selling, General & Admin | 10.28 | 20.26 |
| Total Operating Expenses | 25.62 | 36.92 |
| Operating Income | (22.62) | (17.28) |
| Net Income | (20.19) | (16.63) |
| Basic EPS | (1.18) | (0.97) |
| Diluted EPS | (1.18) | (0.97) |
Cash Flow Statement
(in millions USD)| Metric | Q2
2026 | Q1
2026 |
|---|
| Operating Cash Flow | (3.93) | (31.14) |
| Capital Expenditures | 0.04 | 2.10 |
| Free Cash Flow* | (3.96) | (33.24) |
| Investing Cash Flow | (191.59) | (2.10) |
| Financing Cash Flow | 0.00 | 301.51 |
* Derived from reported values
